A quick summary of the HSV2 vaccine so far folks (as I see it)....

A quick summary of the HSV2 vaccine so far folks (as I see it).

*We do have a HSV2 vaccine (COR1)
*We do have interim results (being from 20 participants).
*We know that the decrease in viral shedding (VS) was 58% (and there were no safety issues).
*We await final results (from the full 36 participants). We very much hope there are no safety issues. And hopefully viral shedding is not much lower than 58%.
*This is not a cure for HSV2 but a vaccine to limit infecting others.
*There are already HSV2 anti-viral drugs on the market (75% lower VS).
*The AHZ vaccine could be teamed with the anti-viral drugs to give a higher overall decrease in VS.
*Different vaccine doses / different injection sites / different methods of vaccine entry to body / etc etc would almost certainly improve VS decrease.
*We know the underlying patented 'platform technology' works and will be applicable to fighting other viruses.
*A Phase 3 trial is way too expensive for AHZ and we need a big pharma partner.
*The CEO and Board have the global contacts, reputation, experience to get this joint- venture and on the best possible terms.

We await the final results and hope there are no safety concerns AND that the VS decrease rate is about 60%.